View More Recent Stories
-
Citizens JMP Reiterates Market Outperform Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals (TERN) PT Lowered to $15 at BMO Capital
-
Terns Pharmaceuticals, Inc. (TERN) Tops Q1 EPS by 4c
-
Citizens JMP Reiterates Market Outperform Rating on Terns Pharmaceuticals (TERN)
-
Mizuho Reiterates Outperform Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals, Inc. (TERN) Tops Q4 EPS by 6c
-
Will Pfizer step into the obesity ring? Wolfe Research answers
-
Terns Pharmaceuticals (TERN) Provides Program Updates
-
Terns Pharmaceuticals Inc. (TERN) Appoints Andrew Gengos as CFO
-
Oppenheimer Reiterates Outperform Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals (TERN) PT Raised to $20 at Oppenheimer
-
Terns Pharmaceuticals Inc. (TERN) Reports Positive Early Data from Phase 1 CARDINAL Trial of TERN-701
-
Terns Pharmaceuticals Inc. (TERN) Appoints Heather Turner to its Board
-
Terns Pharmaceuticals (TERN) PT Raised to $7.50 at H.C. Wainwright
-
Oppenheimer Starts Terns Pharmaceuticals (TERN) at Outperform
-
Terns Pharmaceuticals (TERN) PT Raised to $14 at Mizuho
-
Terns Pharmaceuticals Inc. (TERN) Prices Upsized 11.92M Share Offering at $10.50/sh
-
Mizuho Reiterates Outperform Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals Inc. (TERN) Announces Proposed $125M Share Offering
-
Terns Pharmaceuticals (TERN) PT Raised to $30 at Jefferies Following +16% Gain Today
-
Terns Pharmaceuticals Inc. (TERN) Climbs 29% Following Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
-
Terns Pharmaceuticals (TERN) Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
-
TD Cowen Reiterates Buy Rating on Terns Pharmaceuticals (TERN)
-
Mizuho Adds New Names to Top Pick List
-
Mizuho Reiterates Outperform Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals Inc. (TERN) spreaders active in September 10 and 17 calls
-
Terns Pharmaceuticals, Inc. (TERN) Tops Q2 EPS by 3c
-
Terns Pharmaceuticals, Inc. (TERN) Tops Q2 EPS by 3c
-
Terns Pharmaceuticals (TERN) Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
-
Terns Pharmaceuticals (TERN): Kenneth Griffin Reports 5.3% Stake

